Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2005 Jul;66(4):279–293. doi: 10.1016/j.curtheres.2005.08.013

Effects of zafirlukast on the function of humanpolymorphonuclear neutrophil leukocytes in asthmatic patients: A prospective, controlled, in vitro study

Hana A Al-Zamil 1,*, Ali S Ai-Twaijiri 1, Abdulla F Al-Mobeireek 2, Ali A Mustafa 3
PMCID: PMC3964553  PMID: 24672130

Abstract

Background:

Reactive oxygen species (ROSS) play an important role in the pathogenesis of asthma, and oxidative stress contributes to the initiation and worsening of inflammatory respiratory disorders (eg, asthma). Thus, antioxidant drugs may have a role in reducing or preventing damage in asthma.

Objective:

The aim of the study was to investigate the antioxidant effect of zafirlukast, a leukotriene receptor antagonist, in asthma.

Methods:

This prospective, controlled, in vitro study was conducted at KingKhalid University Hospital, Riyadh, Saudi Arabia. The generation of ROSS by polymorphonuclear neutrophil leukocytes (PMNs) in patients with mild to moderate asthma (forced expiratory volume in 1 second [FEVI], >70% of the predicted value) and healthy volunteers was assessed using chemiluminescence (CL) with phorbol 12-myristate 13-acetate (PMA) and opsonized zymosan (OPZ) in the presence of different concentrations of zafirlukast (1.25-60 μg/mL). The xanthine/xanthine oxidase (X-XOD) reaction was used to test the scavenging effect of the drug.

Results:

Six asthmatic patients (4 women, 2 men; mean age, 30.8 years; meanFEVI, 82.5% of the predicted value) and 8 healthy volunteers (4 women, 4 men; mean age, 28.8 years) were enrolled. A dose-dependent inhibition of the CL response was observed in both groups. However, patients with asthma required higher concentrations of zafirlukast to achieve an inhibitory effect similar to that in healthy controls. This difference was significant at concentrations of 20 to 60 μg/mL (all, P ≤ 0.05). When PMNs were challenged with OPZ, inhibition was also dose dependent in controls at all concentrations (all, P ≤ 0.05), but the inhibitory effect was not significant in the asthmatic patients at any concentration. The difference in the inhibitory effect between the 2 groups was significant at 30, 40, and 60 μg/mL (P < 0.02, <0.01, and <0.01, respectively). The mean (SEM) viability of the PMNs in the healthy controls was significantly affected only at the highest concentration compared with the control saline dose (86.5% [5.8%] vs 97.0% [8.%]; P < 0.05). No scavenging effect of zafirlukast was found using the X XOD system. Incubating PMA-stimulated cells with zafirlukast (5 and 10 μg/mL) for 10 minutes to 1 hour significantly increased the inhibitory effect of the drug by 15% to 46% (all, P < 0.001). When zafirlukast was tested for reversibility of its inhibitory effect on ROS production, its action was found to be irreversible at a concentration of 30 μg/mL (P < 0.001) and partially reversible at 60 μg/mL compared with the baseline saline control.

Conclusions:

Zafirlukast inhibited ROS generation by PMNs in a dose-dependentmanner in asthmatic patients and healthy subjects. However, asthmatic patients required much higher concentrations compared with controls. The incubation of the stimulated cells with zafirlukast increased the inhibitory effect. This finding suggests that the therapeutic effect of zafirlukast in asthma may be in part related to its antioxidant action.

Key words: zafirlukast, polymorphonuclear leukocytes, asthmatic patients, reactive oxygen species, healthy volunteers, chemiluminescence

Full Text

The Full Text of this article is available as a PDF (817.7 KB).

References

  • 1.Gern J.E., Lemanske R.F., Jr, Busse W.W. Early life origins of asthma. J Clin Invest. 1999;104:837–843. doi: 10.1172/JCI8272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Hanazawa T., Kharitonov S.A., Barnes P.J. Increased nitrotyrosine in exhaled breath condensate of patients with asthma. Am J Respir Crit Care Med. 2000;162:1273–1276. doi: 10.1164/ajrccm.162.4.9912064. [DOI] [PubMed] [Google Scholar]
  • 3.Henson P.M., Wenzel S.E. Neutrophils and their mediators in asthma. In: Busse W.W., Holgate S.T., editors. Asthma and Rhinitis. 2nd ed. Blackwell Science; Oxford, United Kingdom: 2000. pp. 503–517. [Google Scholar]
  • 4.Surette M.E., Krump E., Picard S., Borgeat P. Activation of leukotriene synthesis in human neutrophils by exogenous arachidonic acid: Inhibition by adenosine A(2a) receptor agonists and crucialrole of autocrine activation by leukotriene B(4) Mol Pharmacol. 1999;56:1055–1062. doi: 10.1124/mol.56.5.1055. [DOI] [PubMed] [Google Scholar]
  • 5.Hay D.W., Torphy T.J., Undem B.J. Cysteinyl leukotrienes in asthma: Old mediators up to new tricks. Trends Pharmacol Sci. 1995;16:304–309. doi: 10.1016/s0165-6147(00)89059-8. [DOI] [PubMed] [Google Scholar]
  • 6.Menard G., Bissonnette E.Y. Priming of alveolar macrophages by leukotriene D(4): Potentiation of inflammation. Am J Respir Cell Mol Biol. 2000;23:572–577. doi: 10.1165/ajrcmb.23.4.4152. [DOI] [PubMed] [Google Scholar]
  • 7.Johnson H.G., McNee M.L. Secretogogue responses of leukotriene C4, D4: Comparison of potency in canine trachea in vivo. Prostaglandins. 1983;25:237–243. doi: 10.1016/0090-6980(83)90107-7. [DOI] [PubMed] [Google Scholar]
  • 8.Marom Z., Shelhamer J.H., Bach M.K. Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis. 1982;126:449–451. doi: 10.1164/arrd.1982.126.3.449. [DOI] [PubMed] [Google Scholar]
  • 9.O'Byrne P.M., Israel E., Drazen J.M. Anti leukotrienes in the treatment of asthma. Ann Intern Med. 1997;127:472–480. doi: 10.7326/0003-4819-127-6-199709150-00009. [DOI] [PubMed] [Google Scholar]
  • 10.Lockhart A., Dinh-Xuan A.T. Physiopathology of asthma: What role for leukotrienes? Rev Pneumol Clin. 1997;53:119–127. [in French] [PubMed] [Google Scholar]
  • 11.Leff J.A. Leukotriene modifiers as novel therapeutics in asthma. Clin Exp Allergy. 1998;28(Suppl 5):147–153. doi: 10.1046/j.1365-2222.1998.028s5147.x. [DOI] [PubMed] [Google Scholar]
  • 12.Weiss E.B., Bellino J.R. Leukotriene-associated toxic oxygen metabolites induce airway hyperreactivity. Chest. 1986;89:709–716. doi: 10.1378/chest.89.5.709. [DOI] [PubMed] [Google Scholar]
  • 13.Lipworth B.J. The emerging role of leukotriene antagonists in asthma therapy. Chest. 1999;115:313–316. doi: 10.1378/chest.115.2.313. [DOI] [PubMed] [Google Scholar]
  • 14.Edelman J.M., Turpin J.A., Bronsky E.A., Exercise Study Group Oral montelukast compared with inhaled salmeteroI to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Ann Intern Med. 2000;132:97–104. doi: 10.7326/0003-4819-132-2-200001180-00002. [DOI] [PubMed] [Google Scholar]
  • 15.Calhoun W.J. Summary of clinical trials with zafirlukast. Am J Respir Crit Care Med. 1998;157:5238–5246. (Suppl) [PubMed] [Google Scholar]
  • 16.Busse W.W., McGill K.A., Horwitz R.J. Leukotriene pathway inhibitors in asthma and chronic obstructive pulmonary disease. Clin Exp Allergy. 1999;29:110–115. doi: 10.1046/j.1365-2222.1999.00019.x. [DOI] [PubMed] [Google Scholar]
  • 17.Cakmak G., Demir T., Gemicioglu B. The effects of add-on zafirlukast treatment to budesonide on bronchial hyperresponsiveness and serum levels of eosinophilic cationic protein and total antioxidant capacity in asthmatic patients. Tohoku J Exp Med. 2004;204:249–256. doi: 10.1620/tjem.204.249. [DOI] [PubMed] [Google Scholar]
  • 18.Hasegawa H., Suzuki K., Nakaji S., Sugawara K. Analysis and assessment of the capacity of neutrophils to produce reactive oxygen species in a 96-well microplate format using lucigenin- andluminol-dependent chemiluminescence. J Immunol Methods. 1997;210:1–10. doi: 10.1016/s0022-1759(97)00159-2. [DOI] [PubMed] [Google Scholar]
  • 19.Van Dyke K., Van Dyke C., Udeinya J. A new screening system for nonsteroidal anti-inflammatory drugs based upon inhibition of chemiluminescence produced from human cells (granulocytes) Clin Chem. 1997;25:1655–1661. [PubMed] [Google Scholar]
  • 20.Gionchetti P., Guarnieri C., Campieri M. Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation. Dig Dis Sci. 1991;36:174–178. doi: 10.1007/BF01300752. [DOI] [PubMed] [Google Scholar]
  • 21.Braga P.C., Dal Sasso M., Dal Negro R. Inhibitory effects of zafirlukast on respiratory bursts of human neutrophils. Drugs Exp Clin Res. 2002;28:133–145. [PubMed] [Google Scholar]
  • 22.Della Bianca V., Grzeskowiak M., Dusi S., Rossi F. Transmembrane signaling pathways involved in phagocytosis and associated activation of NADPH oxidase mediated by Fc gamma Rs in human neutrophils. J Leukoc Biol. 1993;53:427–438. doi: 10.1002/jlb.53.4.427. [DOI] [PubMed] [Google Scholar]
  • 23.Sala A., Folco G. Neutrophils, endothelial cells, and cysteinyl leukotrienes: A new approach to neutrophil-dependent inflammation? Biochem Biophys Res Commun. 2001;283:1003–1006. doi: 10.1006/bbrc.2001.4865. [DOI] [PubMed] [Google Scholar]
  • 24.Raulf M., Konig W. Modulation of leukotriene release from human polymorphonuclear leucocytes by PMA and arachidonic acid. Immunology. 1988;64:51–59. [PMC free article] [PubMed] [Google Scholar]
  • 25.Werz 0., Klemm J., Samuelsson B., Radmark 0. Phorbol ester up-regulates capacities for nuclear translocation and phosphorylation 5-lipoxygenase in Mono Mac 6 cells and human polymorphonuclear leukocytes. Blood. 2001;97:2487–2495. doi: 10.1182/blood.v97.8.2487. [DOI] [PubMed] [Google Scholar]
  • 26.Kato M., Nakano M., Morikawa A. Ability of polymorphonuclear leukocytes to generate active oxygen species in children with bronchial asthma. Use of chemiluminescence probes with aCypridina luciferin analog and luminol. Int Arch Allergy Appl Immunol. 1991;95:17–22. doi: 10.1159/000235448. [DOI] [PubMed] [Google Scholar]
  • 27.Berends C., Hoekstra M.O., Dijkhuizen B. Expression of CD35 (CR1) and CD11b (CR3) on circulating neutrophils and eosinophils from allergic asthmatic children. Clin Exp Allergy. 1993;23:926–933. doi: 10.1111/j.1365-2222.1993.tb00277.x. [DOI] [PubMed] [Google Scholar]
  • 28.Di Gennaro A., Carnini C., Buccellati C. Cysteinyl-leukotrienes receptor activation in brain inflammatory reactions and cerebral edema formation: A role for transcellular biosynthesis ofcysteinyl-leukotrienes. FASEB J. 2004;18:842–844. doi: 10.1096/fj.03-0599fje. [DOI] [PubMed] [Google Scholar]
  • 29.Steinke J.W., Borish L. Leukotriene receptors in rhinitis and sinusitis. Curr Allergy Asthma Rep. 2004;4:217–223. doi: 10.1007/s11882-004-0029-x. [DOI] [PubMed] [Google Scholar]
  • 30.Accomazzo M.R., Rovati G.E., Vigano T. Leukotriene D4-induced activation of smooth-muscle cells from human bronchi is partly Ca2+-independent. Am J Respir Crit Care Med. 2001;163:266–272. doi: 10.1164/ajrccm.163.1.9912019. [DOI] [PubMed] [Google Scholar]
  • 31.Figueroa D.J., Breyer R.M., Defoe S.K. Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes. Am J Respir Crit Care Med. 2001;163:226–233. doi: 10.1164/ajrccm.163.1.2003101. [DOI] [PubMed] [Google Scholar]
  • 32.Minoguchi K., Adachi M. Leukotriene modifiers. Nippon Rinsho. 2001;59:1979–1985. [in Japanese] [PubMed] [Google Scholar]
  • 33.Bouchelouche P.N., Berild D. Possible existence of leukotriene D4 receptors and mechanism of their signal transduction in human polymorphonuclear leukocytes. Scand J Clin Lab Invest Suppl. 1991;204:47–55. doi: 10.3109/00365519109104594. [DOI] [PubMed] [Google Scholar]
  • 34.Baud L., Koo C.H., Goetzl E.J. Specificity and cellular distribution of human polymorphonuclear leucocyte receptors for leukotriene C4. Immunology. 1987;62:53–59. [PMC free article] [PubMed] [Google Scholar]
  • 35.Raulf M., Stuning M., Konig W. Effect of cations on leukotriene release: Requirements for the metabolism of peptide-leukotrienes (leukotrienes C4, D4) by human polymorphonuclear granulocytes. Immunology. 1986;58:479–487. [PMC free article] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES